Chang H, Blondal J A, Benchimol S, Minden M D, Messner H A
Ontario Cancer Institute/Institute of Medical Science, University of Toronto, Canada.
Leuk Lymphoma. 1995 Sep;19(1-2):165-71. doi: 10.3109/10428199509059672.
Fourteen Non-Hodgkin's lymphoma cell lines were generated and assessed for the presence of structural p53, c-myc and bcl-2 gene changes. Single or multiple changes were observed in 11 of the lines. Alterations of the p53 gene were most frequent and documented for 10 lines by immunoprecipitation using the antibodies PAb 240 and PAb 1801, sequencing studies and Southern blot analysis. A detailed study was performed in one of the cell lines (OCI-Ly 4) for which material of the original tumor sample was available. Two point mutations identified by sequencing cDNA derived from the cell line were also present in the original tumor specimen. In contrast, DNA prepared from fibroblasts of the same patient did not show the mutations. Six of the 14 lines demonstrated c-myc rearrangements, while bcl-2 changes were observed in 4. The presence of c-myc was associated with shorter survival of this group of patients with aggressive disease. None of the other changes present as single or composite alterations were correlated with clinical outcome measures.
建立了14种非霍奇金淋巴瘤细胞系，并对其p53、c-myc和bcl-2基因的结构改变进行评估。在11种细胞系中观察到单一或多个改变。p53基因的改变最为常见，通过使用抗体PAb 240和PAb 1801进行免疫沉淀、测序研究和Southern印迹分析，在10种细胞系中得到证实。对其中一种细胞系（OCI-Ly 4）进行了详细研究，该细胞系有原始肿瘤样本材料。通过对该细胞系来源的cDNA测序鉴定出的两个点突变也存在于原始肿瘤标本中。相比之下，从同一患者的成纤维细胞制备的DNA未显示出这些突变。14种细胞系中有6种显示c-myc重排，4种观察到bcl-2改变。c-myc的存在与这组侵袭性疾病患者的较短生存期相关。作为单一或复合改变出现的其他改变均与临床结局指标无关。
